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Abstract:  The design, development and clinical success of HIV protease inhibitors 
represent one of the most remarkable achievements of molecular medicine. This review 
describes all nine currently available FDA-approved protease inhibitors, discusses their 
pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The 
compounds in the various stages of clinical development are also introduced, as well as 
alternative approaches, aiming at other functional domains of HIV PR. The potential of 
these novel compounds to open new way to the rational drug design of human viruses is 
critically assessed. 
Keywords:  HIV protease; protease inhibitors; HAART; resistance development; 
pharmacokinetic boosting; protease dimerization; alternative inhibitors 
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Abbreviations 
APV     Amprenavir 
ATV     Atazanavir 
BCV     Brecanavir 
BID     twice per day 
CYP450 3A4    Cytochrome P450/3A4 
DRV     Darunavir 
FDA     Food and Drug Administration 
FPV, fAPV     Fosamprenavir 
HAART     Highly active antiretroviral therapy 
IDV     Indinavir 
Kd   Dissociation  constant 
Ki     Inhibition constant 
LPV     Lopinavir 
NFV     Nelfinavir 
PIs     Protease inhibitors 
PR     Protease 
q24h     every 24 hours 
RTV     Ritonavir 
SQV     Saquinavir 
TPV     Tipranavir 
1. Introduction  
The aspartic protease of human immunodeficiency virus (HIV PR) is responsible for the cleavage of 
the viral Gag and Gag-Pol polyprotein precursors into mature, functional viral enzymes and structural 
proteins. This process, called viral maturation, which leads to the final morphological rearrangements, 
is indispensable for production of infectious viral particles [1]. If HIV-PR is inhibited, the nascent 
virions cannot go on to attack other cells and the spreading of HIV is therefore stopped. The 
introduction of HIV protease inhibitors (PIs) in 1995 and the application of highly active anti-retroviral 
therapy (HAART), i.e., combination of PI with other antiretrovirals, mainly inhibitors of the HIV 
reverse transcriptase, resulted in a vastly decreased mortality (Figure 1) and a prolonged life 
expectancy of HIV-positive patients. The success story of the therapeutic use of HIV protease 
inhibitors is not only a remarkable achievement of modern molecular medicine, but it also represents a 
unique showcase for the power and limitations of a structure-based drug design in general. 
Although the success of HIV PIs has been remarkable and there are not fewer than nine of these 
compounds currently approved by the FDA as antiviral agents, for several reasons both the academia 
as well as the industry need to continue in their effort to develop novel, more potent compounds.  
First, there is a problem of antiviral drug resistance. The high mutation rate caused by the lack of 
proofreading activity of the viral reverse transcriptase, the dynamic viral replication in HIV-positive 
individuals, together with potential dual infection and insufficient effect of drugs lead to rapid Viruses 2009, 1                  
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selection of viral species resistant to the currently used inhibitors. The pattern of mutations associated 
with the viral resistance is extremely complex (Figure 2, Table 1). The mutations are selected not only 
in the protease substrate binding cleft in the direct proximity of an inhibitor, but also outside the active 
site of the enzyme. Besides the common mechanism of amino acid substitution, insertions in the PR 
have also been observed to be selected during antiretroviral therapy [2,3]. Furthermore, HIV 
occasionally rescues its fitness under the selection pressure of PIs by changing the protease substrate, 
i.e., the polyprotein cleavage sites [4,5]. Some of these gag mutations have been shown to confer the 
viral resistance even without the corresponding changes in the PR [6]. The mechanism of resistance 
development and the structural aspects of the interaction of PIs with the active cleft of mutated HIV 
PR species are discussed in other reviews in this volume.  
Figure 1. Trends in annual rates of death due to 7 leading causes among persons 25-44 
years old in the United States during period 1987-2004. Dramatic decrease in the rate of 
death due to AIDS coincides with the introduction of HIV protease inhibitors (source: 
National Vital Statistics, Centers for Disease Control and Prevention, Atlanta). 
 
 
Secondly, the clinical use of PIs is further affected by their high price and by problems of 
tolerability, toxicity, and adherence. Before the introduction of the first PIs into the clinical practice, 
optimistic expectations prevailed that the toxicity of this class of virostatics will be low because of the 
absence of enzymes similar to HIV protease in the human body. Unfortunately, the reality was 
different, and soon it turned out that compounds can interact with other molecules, particularly in the 
lipid metabolism and trafficking pathways. Consequently, the side effects of PIs are very frequent and 
often so serious that the drug toxicity may sometimes represent even a greater risk for patients than the Viruses 2009, 1                  
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HIV infection itself [10-12]. The presence of side effects together with the pill burden negatively 
influence the patient’s adherence and hence contribute to the evolution of resistance.  
Taken together, inspite of the indisputeble success of the HAART and benefit to patients, new 
approaches to the antiviral treatment, including novel HIV PIs, are highly desirable to achieve better 
control of HIV infection while maintaining acceptable quality of patient’s life. Novel PIs should be 
developed with broad specificity against PI-resistant HIV mutants, better pharmacokinetic properties, 
lower toxicity, and simple dosage. 
In the following contribution, we will briefly review the PIs that are currently used clinically, and 
we will also mention some other compounds that entered various stages of clinical testing. 
Subsequently, we will provide an overview of selected experimental HIV PIs targeting the enzyme 
active site as well as other functionally important regions, namely the protease dimerization and flap 
domains. 
Figure 2. The three-dimensional crystal structure of HIV PR dimer depicting mutations 
associated with resistance to clinically used protease inhibitors [7]. Mutated residues are 
represented with their Cα atoms (spheres) and colored in the shades of red and blue for 
major and minor mutations, respectively. For major mutations, the semi-transparent 
solvent accessible surface is also shown in red. Active site aspartates and PI darunavir 
bound to the active site are represented in stick models. The figure was generated using 
the structure of highly mutated patient derived HIV-1 PR (PDB code 3GGU [8]) and 
program PyMol [9]. 
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Table 1. Mutations in the protease gene associated with resistance to PIs
 a. 
PI
b Major  mutations
c Minor  mutations
d 
Atazanavir  
+/- ritonavir 
50, 84, 88 
10, 16, 20, 24, 32, 33, 34, 36, 46, 48, 53, 54, 60, 
62, 64, 71, 73, 82, 85, 90, 93 
Darunavir
e  50, 54, 76, 84  11, 32, 33, 47, 74, 89 
Fosamprenavir
e  50, 84  10, 32, 46, 47, 54, 73, 76, 82, 90 
Indinavir
e  46, 82, 84  10, 20, 24, 32, 36, 54, 71, 73, 76, 77, 90 
Lopinavir
e  32, 47, 82 
10, 20, 24, 33, 46, 50, 53, 54, 63, 71, 73, 76, 84, 
90 
Nelfinavir  30, 90  10, 36, 46, 71, 77, 82, 84, 88 
Saquinavir
e  48, 90  10, 24, 54, 62, 71, 73, 77, 82, 84 
Tipranavir
e   33, 47, 58, 74, 82, 84  10, 13, 20, 35, 36, 43, 46, 54, 69, 83, 90 
a Adapted from International AIDS society reports [7]  
b Ritonavir is not listed separately as it is currently used only as a pharmacologic booster of other PIs (in low dose).  
c  Major mutations are those selected first in the presence of the drug or those substantially reducing drug 
susceptibility. 
d  Minor mutations emerge later and do not have a substantial effect on virus phenotype. They may improve 
replication capacity of viruses containing major mutations. 
e PIs used in co-formulation with ritonavir. 
2. Inhibitors currently used in clinical practice: structure, antiviral activity, side-effects, and 
pharmaceutical boosting 
Since the identification of HIV as an etiological entity of AIDS, more than twenty different drugs 
have been introduced into the clinical practice. Such drugs inhibit specific steps in viral lifecycle and 
thus the replication of the virus. In fact, more virostatics are available for HIV/AIDS than for all other 
viruses combined. This exciting endeavor has been extensively reviewed [13-21]. In developed 
countries, HAART considerably changed the course of HIV infection to a controllable and treatable 
long-term disease.  
Nine protease inhibitors are currently on the market (see Table 2). They are competitive inhibitors 
of HIV PR and all but one are peptidomimetics of the polyprotein cleavage sites. The first true non-
peptidic inhibitor is tipranavir, which was approved in 2005. The currently available PIs are also active 
against the HIV-2 protease, but with some exceptions – e.g., lopinavir is less effective in the therapy of 
HIV-2 infection [22]. As mentioned above, important characteristics of any drug that are very relevant 
for its clinical application are toxicity and undesired side effects. The pathogenesis of some side effects 
has already been satisfactorily explained (e.g., indinavir nephrolithiasis occasionally caused by 
indinavir), but pathogenetic mechanisms of numerous side effects (e.g., lipodystrophy syndrome, 
insulin resistance, inhibition of glucose uptake or disturbances of bone metabolism) is still not entirely 
elucidated [23-26] , reviewed in [21] . Viruses 2009, 1                  
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Table 2. Overview of the inhibitors of HIV protease approved for clinical use with their 
dosage, side effects, and the position in the present therapeutic arsenal, elaborated with 
regard to the recommendations of the US Department of Health and Human Services 
[Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
antiretroviral agents in HIV-1-Infected adults and adolescents. Department of Health and 
Human Services. November 3, 2008; 1-139. Available online: 
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. (Accessed 12 
September 2009)] 
Generic name 
and 
abbreviation 
Commonly 
recommended 
dosage 
Most common side effects and  
off-target activities 
Position in the 
present therapeutic 
arsenal 
Ritonavir 
(RTV)
a 
100–200 mg p.o. BID 
as pharmacokinetic 
booster of various PIs 
(original 
pharmacodynamic 
dose was 600 mg p.o. 
BID) 
nausea, diarrhea, abdomenalgia, 
hyperlipidemia, lipodystrophy 
syndrome, 
inhibition of the cytochrome P450 
3A4 
practically only 
pharmacoenhancing 
of various PIs 
Saquinavir 
(SQV) 
1000 mg +  
RTV 100 mg p.o. BID
 
diarrhea, hyperlipidemia, 
lipodystrophy syndrome 
 
second-line HAART 
therapy 
Indinavir 
(IDV) 
800 mg + 
RTV 100 mg p.o. BID
nephrolithiasis, lipodystrophy 
syndrome, hyperlipideamia, 
hepatotoxicity 
second/third-line 
HAART therapy in 
case of resistance or 
intolerance 
Nelfinavir 
(NFV) 
1250 mg p.o. BID  diarrhea, hyperlipidemia, 
lipodystrophy syndrome 
 
second/third-line 
HAART therapy in 
case of resistance or 
intolerance, 
approved for therapy 
of children 
Lopinavir 
(LPV/r)
 b  
400 mg +  
RTV 100 mg p.o. BID
diarrhea, hyperlipideamia, 
 lipodystrophy syndrome 
 
first line option for PI 
based HAART 
regimen 
Amprenavir 
(APV) 
600 mg +  
RTV 100 mg p.o. BID
diarrhea, toxoallergic rash, 
hyperlipidemia, lipodystrophy 
syndrome 
 
replaced by its 
prodrug fos-
amprenavir 
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Table 2. Cont. 
Generic name 
and 
abbreviation 
Commonly 
recommended 
dosage 
Most common side effects and  
off-target activities 
Position in the 
present therapeutic 
arsenal 
Fos-
amprenavir 
(FPV) 
700 mg p.o. +  
RTV 100 mg p.o. BID
diarrhea, toxoallergic rash, 
hyperlipidemia, lipodystrophy 
syndrome 
first-line option for PI 
based HAART 
regimen 
Atazanavir 
(ATV) 
300 mg +  
RTV 100 mg p.o. 
q24h or 
400 mg p.o. q24h 
hyperbilirubinemia, 
ECG abnormalities  
(1° atrioventricular block) 
 
first-line option for PI 
based HAART 
regimen 
Tipranavir 
(TPV) 
500 mg +  
RTV 200 mg p.o. BID
toxoallergic rash, hepatotoxicity, 
intracranial hemorrhage, 
lipodystrophy syndrome, diarrhea 
second-line HAART 
therapy in case of 
resistance 
Darunavir 
(DRV) 
600 mg +  
RTV 100 mg p.o. BID 
or 
800 mg +  
RTV 100 mg p.o. 
q24h 
nausea, diarrhea , hyperlipidemia, 
headache, toxoallergic rash 
recently approved for 
first-line HAART 
Abbreviations: BID - twice per day, q24h - every 24 hours 
a Ritonavir is at present used in therapy of HIV infection practically only as a pharmacokinetic booster. 
b Lopinavir is marketed by the manufacturer only as (Kaletra
), in co-formulation together with low doses of ritonavir 
which acts as a pharmacokinetic booster.  
 
All PIs in current clinical practice have been approved only for oral administration, but their 
absorption in the gastrointestinal tract and diffusion through anatomical barriers is usually poor to 
moderate. This effect is partly due to their extensive binding to plasma proteins (90–99%), partly due 
to the binding to P-glycoprotein and consequent eflux of the drug [27]. These factors make their 
effective concentration low, particularly in sanctuary sites such as the central nervous system [28] or 
the genital tract [29,30]. In order to suppress viral infection, drug levels above suitable inhibitory 
concentration must be achieved and maintained in the bloodstream as well as in the virus sanctuary 
sites. Lower drug concentrations in the target sites might lead to ongoing viral replication and enable 
the emergence of drug-resistant variants of the virus. It is therefore very important that many 
pharmacokinetic limitations of PIs can be partially overcome by co-administration with low doses of a 
pharmacokinetic enhancer, or “booster”, a potent inhibitor of cytochrome P450 such as ritonavir   
(see below). Ritonavir-boosted PI therapy leads to simplified treatment regimens, reduced pill burden, 
and, consequently, better patient adherence. This, in turn, helps to prevent the emergence of antiviral 
resistance. At present, all currently marketed PIs, with the exception of nelfinavir, are prescribed with 
a low dose (100 mg per day) of ritonavir as a booster. Although the mechanism of P450 inhibition by 
ritonavir (RTV), originally developed as HIV PR inhibitor, is not fully understood, rational design of Viruses 2009, 1                  
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cytochrome P450 inhibitors has become a very active research field in current pharmaceutical science 
[31] (for recent review see [32,33]). Several promising compounds are currently in various stages of 
clinical testing (e.g., Gilead Sciences’ GS-9350, SPI-452 from Sequoia Pharmaceuticals, TMC-41629 
from Tibotec, PF-03716539 from Pfizer, as well as some others, reviewed in [21,32]. 
On the other hand, any co-administration of these “boosters” with drugs metabolized by cytochrome 
P450 isoenzyme 3A4 may be problematic and lead to severe side-effects. There have been reports on 
serious and even life-threatening events following co-administration of PIs with hypolipidemics 
(HMG-coA reductase inhibitors), antihistamines, or ergot alkaloids. Numerous other drugs, such as, 
e.g., sildenafil, corticosteroids, or psychotropic agents [34], also need to be prescribed with caution to 
patients on HAART therapy involving pharmacokinetic boosters. 
2.1. The first generation HIV protease inhibitors 
The design of the first protease inhibitor saquinavir (SQV, Ro-31-8959, marketed by Hoffman-La 
Roche), which was approved by the FDA in December 1995 under the commercial name Invirase®, 
was based on rather unusual specificity of HIV protease for cleavage of the Phe-Pro and Tyr-Pro bond 
(Figure 3a). The scissile bonds were replaced by a hydroxyethylamine isostere [35]. Despite its high in 
vitro antiviral activity, the clinical efficacy of this drug was significantly reduced due to the 
insufficient bioavailability (less than 4%) and intense hepatic metabolism. In order to improve the 
bioavailability of SQV, a novel formulation of the drug in soft capsules was developed and marketed 
under the name of Fortovase® (Hoffman-La Roche) [36]. Subsequently, SQV was co-formulated with 
with ritonavir as a booster. As of February 15, 2006, the sales of Fortovase were discontinued in the 
United States because of poor drug tolerance; Invirase boosted by ritonavir remained the only drug 
formulation of SQV currently available on the market. 
Typical primary resistance-conferring mutations selected under the pressure of SQV are G48V or 
L90M. The most common adverse reactions reported in patients receiving SQV were gastrointestinal 
disturbances, such as diarrhea, nausea, or abdominal discomfort [37]. 
Ritonavir (RTV, ABT-538) was designed by Abbot laboratories and gained FDA approval in 1996 
under the name Norvir® [38]. The drug design process originally concentrated on C-2 symmetric 
molecules. However, the structures of the inhibitor/enzymes complexes proved that even the most 
active C-2 symmetric compound loses symmetry when bound to the active site of the enzyme. 
Therefore, the final structure of the inhibitor is asymmetrical (Figure 3b), which also enables 
improvement of bioavailability by different modifications of the end groups. Moreover, C-2 symmetric 
compounds would be more sensitive to PR resistance development since every mutation in PR would 
affect the inhibitor binding twice.  
RTV inhibits both HIV-1 and HIV-2 proteases. In vivo, the major observed mutations decreasing 
the susceptibility of enzyme to RTV are I84V and V82A. Ritonavir was originally approved as an 
antiretroviral drug, but due to frequent occurrence of side effects (such as gastrointestinal symptoms 
like nausea, abdomenalgia and diarrhea) and high cross-resistance with other PIs, its use as a HIV-
protease inhibitor was gradually abandoned. Unexpectedly, RTV has proven to be a potent inhibitor of 
cytochrome P-450 3A4, the microsomal enzyme responsible for the bulk of metabolism of other PIs 
(as well as other xenobiotics, see above). Therefore, ritonavir is currently used almost exclusively as a Viruses 2009, 1                  
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pharmacokinetic boosting agent which increases the plasma concentration of other PIs and thus 
prolongs their therapeutic effects [39]. 
Indinavir (IDV, MK-639, L-735,524), manufactured by Merck & Co, was approved in 1996 under 
the trade name Crixivan® [40]. Design of this compound possessing a hydroxyaminopentanamide 
transition state isostere was based on the framework of previously developed renin inhibitors. Physical 
properties,  i.e., solubility and lipophilicity, of optimized molecules were further improved using 
molecular modeling and X-ray crystal structure analysis of the inhibitor/enzyme complexes   
(Figure 3c). Although indinavir used to be among the most widely clinically used first-generation PIs, 
at present it has been almost completely abandoned due to toxicity and frequent side effects. 
Nephrolithiasis is a typical side effect of IDV caused by disturbances of the drug solubility in urine. 
The compound is more soluble in acidic urine due to the presence of the basic polar groups. With the 
increase of the actual pH (>5.5), IDV tends to crystallize in kidneys [41]. Another typical side effect of 
IDV is the lipodystrophy syndrome, characterized by maldistribution of body fat (accumulation in 
abdominal area – “crix belly” and “buffalo hump”) [42].  
The first protease inhibitor which could be used by adults as well as by children was nelfinavir 
(NFV, AG-1343), approved in 1997 and marketed as Viracept®. Developed by Agouron 
Pharmaceuticals by iterative protein co-crystal structure analysis, it was the first PI which structure has 
been optimized by Monte Carlo simulations [43] (Figure 3d). In more than a half of the patients, 
resistance conferring mutation D30N is selected, often accompanied by N88D. The other possible 
pathway leading to NFV resistance involves the selection of L90M mutation. Interestingly, these two 
pathways seem to be mutually exclusive [44]. The therapeutic use of NFV is currently limited because 
of the significantly lower efficacy compared to the recently introduced second generation PIs. The 
major adverse effect of NFV is gastrointestinal toxicity characterized by diarrhea, often of a severe 
grade. Other common side effects are metabolic disturbances, such as lipodystrophy and 
hyperlipidemia [45].  
Amprenavir (APV, 141W94 or VX-478) from Vertex Pharmaceuticals and GlaxoSmithKline has 
been marketed under the name Agenerase® since 1999 [46]. Its central part is derived from SQV, but 
the P2 end group is replaced by tetrahydrofurancarbamate and the P1´-P2´ moiety by a sulfonamide 
derivative (Figure 3e). This structure has some advantages over SQV such as fewer chiral centers, 
easier synthesis, and higher oral bioavailability. Mutations which result in a decrease of susceptibility 
to Agenerase® occur mainly in positions M46I/L, I47V, I50L, I54L/V, and I84V. Mutations 
conferring resistance to APV were also observed in the p1/p6 of the Gag substrate cleavage site, at 
positions L449 and P453 [47]. The adverse events of APV are mainly gastrointestinal, such as loose 
stools and abdominal pain; skin rash is also relatively common. APV administration could also lead to 
hypertriglyceridemia and hypercholesterolemia [48–50]. 
In order to further improve the safety, pharmacokinetics, and therapeutic potency of amprenavir, 
fosamprenavir (FPV,fAPV, GW 433908, VX-175), a hydrophilic phosphate ester prodrug of 
amprenavir, was developed by Vertex Laboratories and GlaxoSmithKline [51] (Figure 3f), and has 
been marketed under the name Lexiva® since 2003. In vivo, FPV is quickly converted to APV by host 
phosphatases during absorption in the gut. Several mutations, namely V32I, I47V/A, I50V, I54L/M, 
L76V and I84 V/A, are relative contraindications to the use of FPV. The side effects of FPV are 
comparable to those of APV [52]. Viruses 2009, 1                  
 
 
1218
Figure 3. Chemical structures of the first generation HIV protease inhibitors. 
 
 
2.2. The second generation HIV protease inhibitors 
The second generation inhibitors were designed to inhibit HIV PR species resistant to the inhibitors 
of the first generation and to introduce well tolerated drugs with minimized side effects and simple 
once-daily dosing, which may improve patients´ adherence to the treatment. 
Lopinavir (LPV, ABT-378) is the second generation inhibitor most widely used in drug-naïve 
patients. Developed by Abbott, it has been marketed in a co/formulation with ritonavir under the name 
Kaletra® since 2000. LPV was designed to inhibit resistant PR species that contain the common 
mutation V82A. The molecular design of LPV was based on the structure of ritonavir and began by 
eliminating the P3 isopropylthiazolyl group of RTV interacting with the V82 residue of the wild-type 
PR. Further replacement of the thiazolylmethoxycarbonyl moiety in the P2’ with 
dimethylphenoxyacetyl group yielded LPV (Figure 4a). The core P1-P1’ positions are thus occupied 
by the same hydroxyethylene peptidomimetic as in RTV [53]. 
At present, Kaletra® is the first choice PI for an initial antiretroviral regimen. The development of 
resistance is associated with accumulation of mutations occurring at nine to eleven positions 
(“lopinavir mutation score”) [54]. Furthermore, a single mutation I47A, contributing to the reduced 
sensitivity of HIV-1 [55-57] and also HIV-2 [58] protease to the LPV, has been reported [59]. 
Nevertheless, this mutation compromises the replication capacity of the corresponding virus ([58] and 
the citations therein), thus explaining its low prevalence in the HIV-positive patients. The side effects Viruses 2009, 1                  
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of LPV are similar to those of other PIs. The major problems are gastrointestinal events, such as 
abdominal pain, gaseous symptoms or diarrhea, and metabolic disturbances like hypercholesterolemia 
and hypertriglyceridemia [60]. 
The structure-based design of atazanavir ( ATV, CGP 73547, BMS-232632) was part of a complex 
exploration of azadipeptide analogues [61] (Figure 4b). Originally developed by Ciba-Geigy and 
marketed since 2003 under the trade name Reyataz® by Bristol-Myers Squibb, atazanavir was the first 
PI that was compatible with once-daily dosing. The compound shows the least binding to the serum 
proteins, minimal effect on insulin-stimulated glucose uptake and appeared to be less likely to cause 
lipodystrophy and high level of cholesterol as side effects. The main mutations contributing to the 
resistance are I50L, I84V, and N88S. In patients treated with ATV, a prominent indirect 
hyperbilirubinaemia frequently occurs, often leading to clinically apparent jaundice. This condition is, 
indeed, not dangerous, but may have an undesirable cosmetic effect, which may discourage the patient 
from the therapy [62].  
A unique compound was designed at Pharmacia & Upjohn and later introduced by Boehringer-
Ingelheim. Tipranavir (TPV, PNU-140690), approved under the name Aptivus® in 2005, is a non-
peptidic inhibitor, belonging to the 4-hydroxy-5,6-dihydro-2-pyrone sulfonamides [63] (Figure 4c). 
Despite its structural differences from the peptidic inhibitors, its interactions with HIV PR are similar 
in many respects, as shown by its crystal structure [64]. Nevertheless, TPV shows considerable activity 
against numerous PI-resistant HIV strains [65]. As many as 16–20 mutations in the protease gene are 
needed for significant decrease of the HIV PR susceptibility [66]. In addition to the gastrointestinal 
and metabolic disturbances that are common for the whole class, the main limitation of the drug is its 
hepatotoxicity [67]. Occasionally, intracranial hemorrhaging has also been reported [68]. Since it is a 
CYP450 3A4 inducer, TPV requires a double dosage of RTV as a pharmacokinetic booster [69].  
The most recently (2006) approved nonpeptidic HIV protease inhibitor is darunavir (DRV, TMC-
114, UIC-94017, trade name Prezista®) [70]. Developed by Tibotec BVBA, formerly Tibotec-Virgo 
NV, it is a structural homolog of TMC-126 (UIC-94003). Both compounds are chemically similar to 
APV, but differ by the presence of a bis-tetrahydrofuranyl moiety, (Figure 4d), which forms a crucial 
hydrogen bonding interactions with the main chain of Asp29 and Asp30 in the PR. These polar 
interactions with the backbone atoms in the PR active site enable DRV to mimic the conserved 
hydrogen bonds of the natural substrates [71]. Its broad specificity against mutated, highly resistant PR 
species could be interpreted by its ability to fit to the proposed ”substrate envelope” within the active 
site [72,73]. Recently, ultra-high resolution crystal structures revealed that DRV binds not only to the 
active-site cavity, but can also occupy a surface pocket formed by one of the flaps (flexible loops 
covering the enzyme active site) [74]. Enzyme kinetic experiments further confirmed the notion that 
both DRV and APV have a second binding site outsite the active cleft [75]. An assay based on 
fluorescent resonance energy transfer suggests that DRV has a dual mechanism of inhibition, as it 
might also be a potential PR dimerization inhibitor [76].  
Even though DRV is chemically related to APV, it binds nearly 100 times more tightly than APV 
and 1,000 times more tightly than SQV, IDV, RTV and NFV to the wild-type HIV-1 protease [77,78]. 
In clinical studies with treatment experienced and naïve individuals, patients developing darunavir 
resistance tend to have a high number of PI resistance-associated mutations. Thus, the genetic barrier 
to the development of resistance, a measure of the difficulty for the virus to escape from the selective Viruses 2009, 1                  
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pressure of the drug by developing mutations, is very high for DRV. The substitutions suggested to be 
critical for the development of DRV resistance were V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, 
T74P, L76V, I84V, and L89V [79-81]. Grantz Saskova et al. have recently characterized a virus strain 
isolated from HIV-positive patient under prolonged treatment by DRV that contained as many as 22 
mutations in the PR region and exhibited pronounced DRV resistance [8].  
The high genetic barrier to the development of resistance, its better clinical efficacy against 
multidrug-resistant HIV variants together with favorable tolerability, safety, and once-daily regime, 
make DRV one of the preferred therapeutic option both for drug-naïve and for highly treatment-
experienced patients. DRV is generally well tolerated, but the main adverse effects are common with 
the other members of the class, such as gastrointestinal symptoms and lipid abnormalities [82].  
Figure 4. Chemical structures of the second generation HIV protease inhibitors. 
 
 
3. Inhibitors of HIV protease in the pipeline 
Some other interesting compounds were recently or are now in various stages of clinical trials. The 
often convoluted history behind the development of individual compounds documents the complex 
requirements for the activity, resistance profile, toxicity, pharmacokinetics, and drug interactions, as 
well as fierce competition in the field.  
Compound PL-100, a lysine-sulfonamide inhibitor with high genetic barrier to the development of 
resistance and with a favorable cross-resistance profile has been developed by Ambrilia Biopharma 
Inc. (formerly Procyon) and licenced by Merck Co. as Mk 8122 [83]. The compound has been 
identified in a compound library based on L-lysine scaffold (Figure 5a). It is highly active against HIV 
PR and numerous resistant mutants and shows high genetic barrier towards the development of 
resistant virus strains. Moreover, it also possesses inhibitory activity against CYP450 3A4/5, which 
brings about the potential of using this compound in a once-daily, un-boosted regime. Crystal structure 
of a complex of HIV PR with a close analog of PL-100, lysine-sulfonamide 8, shows direct H-bond Viruses 2009, 1                  
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interactions with the flap, displacing the conserved flap water molecule [84]. Despite these favorable 
features, Merck announced in the summer of 2008 that it will put “development of PL-100 on hold and 
will concentrate on other PL-100 prodrugs, formulation options, and back-up compounds”. 
Brecanavir (BCV, GW 640385), developed in a collaborative effort of GlaxoSmithKline and 
Vertex, is a tyrosyl-based arylsulfonamide protease inhibitor with relatively low binding to the plasma 
proteins and high affinity against a variety of PI-resistant viral species (Figure 5b). It was reported to 
exhibit higher in vitro potency than APV, IND, LPV, ATV, TPV, and DRV, which makes it the most 
potent and broadly active antiviral agent among the PIs tested in vitro [85]. However, in December 
2006, GSK announced that it discontinued development of BCV, which was then in phase II clinical 
development, “due to insurmountable issues regarding formulation”.  
A structure-based approach at Sequoia Pharmaceuticals, Inc. involved identification of a 
substructure of conserved regions in the PR active site and the design of compounds that would make 
optimal interactions with such a conserved substructure. The aim was to design compounds retaining 
high potency against a variety of PI-resistant HIV strains. This effort lead to discovery of SPI-256 
(Figure 5c). This compound, currently in phase I clinical evaluation, is highly active against wild-type 
and multidrug-resistant HIV PRs, with inhibition constants in the picomolar range. It shows high 
genetic barrier, and exhibits a better resistance profile than any of the current FDA-approved 
compounds when analyzed using PhenoSense assay [86].  
GS 8374, developed at Gilead Sciences [87], is based on the darunavir scaffold (more specifically, 
on TMC 126) with covalent attachment of a phosphonic acid moiety (Figure 5d). The phosphonate 
compound exhibits high affinity to HIV-1 protease, considerable antiretroviral activity, and a more 
favorable cross-resistance profile against clinically relevant PI-resistant HIV-1 strains. Its co-crystal 
structure suggests that the phosphonate group, exposed to the solvent, brings about a favorable change 
in the inhibitor binding entropy after the interaction with mutant enzymes via “anchoring” of the 
inhibitor molecule to the bulk solvent. GS 8374 showed a resistance profile superior to LPV, ATV, and 
DRV when assayed against a panel of highly resistant mutant viruses [88].  
Figure 5. Chemical structures of inhibitors HIV protease in the pipeline. 
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4. Other non-peptidic HIV protease active site inhibitors 
Generally, the design of novel HIV PIs includes efforts to minimize the inhibitor molecular weight, 
maximize its interactions with the backbone of the PR binding cleft while maintaining flexibility for 
better fit to the variable binding clefts of PR resistant species [89]. These general principles are being 
used by scientists from industry and academia in their efforts to design the next generation of HIV PIs.  
The variability of structural motifs used by rational design or selected by library or combinatorial 
screening is enormous, and it is beyond the scope of this review to attempt to cover all promising 
compounds reported up to date. Below we will only mention several interesting recent examples, thus 
exemplifying the variability of approaches and of the resulting chemical structures. Even though it is 
questionable whether any of these compounds will ever enter the market, they still represent important 
contributions to the armamentarium of modern medicinal chemistry. 
Favourable properties of darunavir lead to the development of several follow-up compounds, 
exemplified by GRL series by Ghosh et al. The P2 bis-tetrahydrofuranyl residue of darunavir was 
replaced by its hexahydrocyclopentafuranyl (GRL -06579A) and P2-P1’ positions of the parent 
structure were modified by pyrrolidinone and oxazolidinone derivatives (GRL 02031), retaining high 
antiviral activity and favourable resistance profile [90,91]. 
A very attractive class of compounds, cyclic ureas, was introduced in 1994 by Lam et al. [92]. 
These non-peptidic compounds were designed to include a mimic of the water molecule in the flap-
proximal part of the enzyme active site. Such a water molecule was shown to interact with the main 
chain atoms of the closed flaps for the substrate and almost all peptidic inhibitors. Several cyclic 
compounds were prepared, with analogues including a seven-membered ring containing compounds 
DMP323 [93] and DMP450 (Figure 6) [94]. Hallberg group in Uppsala have used carbohydrates 
(mannitol) as chiral precursors for the synthesis of several cyclic and C2-symmetric urea and 
sulfamide inhibitors [95,96]. Although there is currently no information about any cyclic urea-based 
compounds entering clinical trials, the 7-membered ring of cyclic urea is still being used as an useful 
scaffold for further PI design. 
Figure 6. Chemical structure of DMP450 (Mozenavir (DuPont). 
 
 
In order to enlarge the chemical space available for the design of novel anti HIV molecules, several 
groups used unusual chemistry for the identification of HIV PIs. Surprisingly, even inorganic 
compounds,  Nb-containing polyoxometalates, specifically inhibit HIV PR with submicromolar 
potency in tissue cultures [97]. In this case, the inhibitors were shown to be non-competitive and a 
model suggested binding to the cationic pocket on the outer surface of the flaps (see below). Clearly, Viruses 2009, 1                  
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the active site of HIV PR could also be targeted by compounds with unexpected chemistry. The HIV 
PR binding cleft was shown to accommodate C60 fullerenes, and some fullerene derivatives are indeed 
weak inhibitors of HIV PR [98-100]. In a search for other unconventional chemical structures that 
would fit into the PR binding cleft, and possess favorable pharmacologic properties, Cigler et al. [101] 
recently identified a group of inorganic compounds, icosahedral carboranes, as promising scaffolds 
for PIs. Boron-containing compounds and carboranes specifically have been already utilized in 
medicinal chemistry in boron neutron capture therapy and in radioimaging. Such compounds are also 
used as stable hydrophobic pharmacophores, usually replacing bulky aromatic amino acid side chains 
[102,103]. Bis(dicarbollides) or metallacarboranes that consist of two carborane cages sandwiching the 
central metal atom, were shown to be specific, stable and rather potent inhibitors of HIV PR 
[101,104,105]. A crystal structure revealed binding of two bis(dicarbollide) clusters to hydrophobic 
pockets in the flap-proximal region of the HIV PR active site, “above” the site for conventional active-
site inhibitors (Figure 7). This unusual binding mode might explain the broad inhibition activity of 
metallacarboranes against highly PI-resistant HIV PR variants [104]. 
Figure 7. Crystal structure of metallacarborane inhibitor bound to HIV PR. (a)  Two 
metallacarborane clusters bind to the flap-proximal part of the active site. The HIV PR is 
represented by a ribbon diagram and colored by rainbow from blue to red (N- to C- 
termini), the atoms of the metallacarborane cluster are represented by spheres and colored 
orange for boron atoms, gray for carbon atoms, and blue for cobalt. The structural formula 
is depicted in (b). Hydrogens are omitted for clarity. 
 
 
In order to rationalize the design of new generation PIs, Schiffer and coworkers introduced an 
interesting approach (recently reviewed in [106]). They proposed that a structural space within the HIV 
PR binding cleft, defined by a consensus volume occupied by the natural substrates of the enzyme, 
should represent a spatial constraint for the inhibitor design. If the inhibitor binds within this “substrate 
envelope”, which was identified by a series of detailed structural analyses of enzyme-substrate 
complexes [107], then its activity should not be significantly compromised by mutations in the PR Viruses 2009, 1                  
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binding cleft. Any mutation within the “substrate envelope” would necessarily lead to a substrate 
binding defect. This approach has been tested on a series of compounds based on amprenavir structure 
and designed to fit within the substrate envelope. Some of these compounds exhibited picomolar 
inhibitory constants against a panel of multi-resistant HIV PR variants [108]. 
5. Alternative HIV protease inhibitors targeting functional domains outside the enzyme active 
site 
Several HIV PR regions have been identified that seem to be conserved in all examined HIV 
sequences derived from treatment-naïve patients. They include residues 1-9 and 94-99 (N- and   
C- termini), 21-32 (active site core), 47-56 (flap region) and 78-88 (substrate-binding region) [109]. 
Although the resistant mutations could clearly evolve even in these conserved regions (especially in 
the flap and substrate-binding region), it is tempting to suggest that compounds binding conservative 
domains of the enzyme outside the active site might be “resistance-repellent”. Moreover, inhibitors 
targeted to the domains outside the active cleft might show a synergistic effect to the conventional 
active-site targeted compounds. Finally, blocking an earlier event in the maturation pathway of the 
virus, such as HIV PR dimerization by binding Gag-Pol polyprotein prior viral maturation, might be an 
attractive approach for antiviral therapy. The alternative inhibitor designs have not, as yet, yielded 
any successful drugs. However, the approaches and techniques developed for their creation could be 
proven useful in the future, or in design of inhibitors of other targets.  
5.1. HIV PR dimerization inhibitors 
HIV PR is only active as a dimer in which each of the two catalytic aspartates is contributed by one 
monomer. The determination of the dimer dissociation constant (Kd) has been the goal of considerable 
efforts of many groups, but its value differs substantially depending on the various techniques and 
experimental conditions (reviewed in [110]). The reported Kd values from kinetic studies are typically 
of the order of 10
−7 to 10
−9 M, whereas the values derived from sedimentation analysis are on average 
three orders of magnitude lower [111-117]. It was already suggested in 1990 that blocking 
the dimerization of the protease monomers could be an effective means for inactivating the enzyme 
[118]. The crystal structure of HIV-1 protease [119] shows that the enzyme dimerization interface is 
formed by the -hairpin of the two flaps, catalytic triad, helices (residues 84-93) interacting with 
residues 4-10, and N- and C-terminal -strands (Figure 8a). A four-stranded antiparallel β-sheet 
composed of  the two N-termini (residues 1-4) interdigitating the  two C-termini (residues 96-99) 
(Figure 8b) contributes to 75% of the stabilizing energy [120]. This dimeric interface is conserved 
among most HIV-1 isolates and drug-resistant variants (see Figure 2) and thus represents an attractive 
target for development of ligands preventing dimerization. 
Early studies demonstrated that interface peptides reproducing the native sequence of C-terminal 
and N-terminal fragments act as HIV PR dimerization inhibitors, although in micromolar concentration 
[112,121,122]. Connection of the N- and C- terminal peptides with flexible linkers [123,124] or more 
rigid scaffolds (“molecular tongs“) [125,126] further increased their inhibitory potency. A recent 
study describes novel interfacial peptides tethered through their side chains, with inhibitory potencies 
against the wild-type HIV PR being in low nanomolar range [127]. Viruses 2009, 1                  
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Figure 8. HIV PR dimerization interface. (a) The overall structure of the HIV PR dimer 
with an inhibitor bound in the active site. Monomers are colored blue and red, respectively. 
Regions involved in creation of a dimeric interface are highlighted by darker shades and 
indicated by residue numbers. (b) A detail of the four-stranded antiparallel β-sheet formed 
by interdigitation of C- and N-terminal strands. Monomers are colored blue and red, 
respectively. A hydrogen bonding network is represented by green dashed lines. The figure 
was generated using the structure of highly mutated, patient derived HIV-1 PR (PDB code 
3GGU [8]) and program PyMol [9]. 
 
 
Modification of the termini of an interfacial peptide by attachment of a lipophilic group and alkyl 
chains (e.g., palmitoyl) improves both the inhibitory capacity and the specificity [128,129]. Currently, 
the most potent lipopeptide inhibitors, containing the minimal peptide sequence Leu-Glu-Tyr modified 
on the N-terminus by palmitoyl, attained sub-nanomolar Ki values for the in vitro inhibition of the wild 
type and drug-resistant mutant variants [130]. Irreversible inhibitors, in which the interface peptide is 
able to covalently modify the protein dimeric interface through a disulfide bridge with Cys95, have 
also been described [131].  
Interesting macromolecular inhibitors targeting dimerization domains are fusions of the N-terminal 
HIV-1 PR peptide with a cell permeable domain from HIV-1 Tat [132,133]. Also, an antibody Viruses 2009, 1                  
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recognizing the N terminus of HIV PR (residues 1-7), which inhibits activity of both HIV-1 and HIV-2 
proteases with Ki values in low nano-molar range [134,135], has been reported. The use of the 
antibody as an anti-HIV drug is rather limited, nevertheless its structure [136,137] might be used as a 
lead in design of low-molecular mimics. 
There has been a significant effort to develop dimerization inhibitors of HIV PR and characterize 
their binding on a structural level [138]. Also, there is great interest to develop inhibitors targeting 
protein-protein interfaces in enzymes and other proteins. Several protein–protein interfaces indeed 
became targets for successful drug development, e.g., HIV proteins and intracellular co-factors [139], 
HIV capsid assembly (reviewed in [140]) or herpes virus protease dimerization [141]. These advances 
might positively boost the development of new HIV PR dimerization inhibitors [142]. 
5.2. Inhibitors targeting HIV PR flaps 
Residues 43-58 of HIV PR form an anti-parallel -hairpin referred to as “the flap”. Two flaps 
within a dimer cover the active site cavity and their movement is crucial for binding and release of 
protease substrate. The conformation behavior of this glycine rich region has been extensively studied 
[143,144] and the most populated states are closed and semi-open. The closed state is found when a 
substrate or peptidomimetic inhibitor is bound to the active site (Figure 9b)  while the semi-open 
conformation is most prevalent in the enzyme apo-form (Figure 9a). Since all currently approved FDA 
PIs target the closed conformation, developing of inhibitors targeted to the open flap conformation 
with a different binding mode might be an alternative to circumvent the cross-resistance. 
Recent examples of inhibitors targeting the open-flap conformation are metallacarborane-based 
[101] and pyrrolidine-based [146] compounds. The metallacarboranes described earlier in this review 
bind to the flap-proximal part of the enzyme active site without interaction with the catalytic 
aspartates, while the pyrrolidine diester inhibitors target the catalytic dyad.  
The region preceding the flap in the sequence (residues 34-42) is called the flap elbow (or the 
hinge). It folds into a surface exposed loop with no particular secondary structure which undergoes 
substantial change during flap opening and closing (Figure 9). With the exception of an insertion in 
position 35 [3], no resistance mutations are associated with this region (Figure 2, Table 1). The flap 
elbow thus might represent a promising drug target.  
A monoclonal antibody recognizing an epitope corresponding to residues 36-46 inhibits the activity 
of HIV PR with Ki value in a nanomolar range [147]. The proposed inhibition mechanism based on the 
crystal structure of the antibody fragment in complex with the 36-46 epitope peptide postulates that 
antibody binding prevents flap closure over the active site [148]. An example of another inhibitory 
compound with predicted affinity toward the flap elbow are Nb-containing polyoxometalates [97], 
mentioned above. They inhibit HIV PR with Ki values in a low-nanomolar range and exhibit a non-
competitive mode with stoichiometry 2 inhibitors to 1 PR dimer. Computational studies suggested that 
these compounds bind to a cationic pocket formed by residues Lys41, Lys43, and Lys55.  Viruses 2009, 1                  
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Figure 9. HIV PR flap conformations. (a) Overall structure of the apo-form of the HIV 
PR. The flaps (residues 43-58) in semi-open conformation are highlighted in red, residues 
37-42, so called flap elbows are also indicated. The figure was generated using the 
structure of free HIV-1 PR (PDB code 1HHP [145]) and program PyMol [9]. (b) Overall 
structure of the HIV PR with flaps (in dark green) in closed conformation. Residues 37-42, 
so called flap elbows are also indicated. Inhibitor bound in the enzyme active site is 
omitted from the figure. The figure was generated using the structure of a highly mutated 
patient derived HIV-1 PR (PDB code 3GGU [8]) and program PyMol [9]. 
 
 
6. Conclusions 
Development and clinical application of specific inhibitors of HIV PR almost immediately after the 
identification of HIV PR as a valid pharmaceutical target represents fascinating and, indeed, probably 
the most successful example of rational drug design in the history of biomedicine. There are currently 
nine FDA approved PIs available. In developed countries the protease inhibitors have at present time a 
secure position in the therapeutic armamentarium for both the initial therapy and the second-line and Viruses 2009, 1                  
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salvage treatment. It is also highly probable, that they will keep this position with further development 
of new more effective and less toxic molecules  in the future [149]. Because of their high costs, 
protease inhibitors are in the resource-limited settings used mainly as drugs of the second-line therapy, 
but in the future an increase of their use can be certainly expected [150].  
There is continuous need for the development of safer, cheaper drugs, active against the host of 
multi-resistant HIV species stemming from different virus strains, with high antiviral activity, 
excellent pharmacokinetic properties and little off-target activity, imposing low pill burden and little 
side-effect to the patient. Even if such an ideal drug never materializes, the research on HIV PR and its 
inhibition will continue to provide remarkable wealth of information about ligand-enzyme and protein-
protein interactions, structural plasticity of proteins, mechanism of resistance development, 
pharmacokinetics of a chemotherapeutic in individual compartments of the body, etc. All this 
information could be used (and, indeed, is already being used) for the development of other 
compounds targeted against other pathogens, other enzymes and other, seemingly indomitable human 
diseases. 
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